-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

Benzinga·10/01/2026 11:28:18
Listen to the news
HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.